Does UBLITUXIMAB-XIIY Cause Multiple sclerosis relapse? 9 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Multiple sclerosis relapse have been filed in association with UBLITUXIMAB-XIIY. This represents 1.0% of all adverse event reports for UBLITUXIMAB-XIIY.
9
Reports of Multiple sclerosis relapse with UBLITUXIMAB-XIIY
1.0%
of all UBLITUXIMAB-XIIY reports
0
Deaths
3
Hospitalizations
How Dangerous Is Multiple sclerosis relapse From UBLITUXIMAB-XIIY?
Of the 9 reports, 3 (33.3%) required hospitalization, and 1 (11.1%) were considered life-threatening.
Is Multiple sclerosis relapse Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for UBLITUXIMAB-XIIY. However, 9 reports have been filed with the FAERS database.
What Other Side Effects Does UBLITUXIMAB-XIIY Cause?
Infusion related reaction (481)
Fatigue (48)
Headache (34)
Malaise (22)
Inappropriate schedule of product administration (21)
Product dose omission issue (19)
Asthenia (18)
Drug ineffective (18)
Nausea (18)
Dizziness (17)
What Other Drugs Cause Multiple sclerosis relapse?
DIMETHYL (6,852)
FINGOLIMOD (6,728)
NATALIZUMAB (6,478)
INTERFERON BETA-1A (5,931)
TERIFLUNOMIDE (4,745)
GLATIRAMER (3,695)
DALFAMPRIDINE (3,322)
OCRELIZUMAB (2,326)
OFATUMUMAB (1,525)
INTERFERON BETA-1B (1,229)
Which UBLITUXIMAB-XIIY Alternatives Have Lower Multiple sclerosis relapse Risk?
UBLITUXIMAB-XIIY vs UBROGEPANT
UBLITUXIMAB-XIIY vs ULIPRISTAL
UBLITUXIMAB-XIIY vs UMBRALISIB
UBLITUXIMAB-XIIY vs UMECLIDINIUM
UBLITUXIMAB-XIIY vs UMECLIDINIUM\VILANTEROL TRIFENATATE